#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	5534	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2491	657.2	1	SNP	n	C1184T	0	.	.	1184	1184	C	1649	1649	C	791	C,A	671,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	5534	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2491	657.2	0	HET	.	.	.	C1201T,G	.	1201	1201	C	1666	1666	C	768	C,T,G	494,137,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	8632	23S	2890	2890	99.86	23S.l6.c4.ctg.1	4035	641.4	0	.	n	.	0	T695C	SNP	695	695	T	1253	1253	C	592	C,A	492,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	8632	23S	2890	2890	99.86	23S.l6.c4.ctg.1	4035	641.4	0	.	n	.	0	G1337A	SNP	1337	1337	G	1895	1895	A	736	A	630	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	8632	23S	2890	2890	99.86	23S.l6.c4.ctg.1	4035	641.4	0	.	n	.	0	T1971C	SNP	1971	1971	T	2529	2529	C	855	C,T	729,4	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	8632	23S	2890	2890	99.86	23S.l6.c4.ctg.1	4035	641.4	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	3155	3155	T	728	T,G	618,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	8632	23S	2890	2890	99.86	23S.l6.c4.ctg.1	4035	641.4	1	SNP	n	A2045G	0	.	.	2045	2045	A	2603	2603	A	863	A,C	739,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	958	folP	852	852	100.0	folP.l15.c4.ctg.1	2032	141.1	1	SNP	p	R228S	1	.	.	682	684	AGC	1264	1266	AGC	195;196;196	A,C;G,T;C	167,1;168,1;170	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1964	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3689	158.9	1	SNP	p	S91F	0	.	.	271	273	TCC	764	766	TCC	159;161;162	T;C;C	130;137;146	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1964	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3689	158.9	1	SNP	p	D95N	0	.	.	283	285	GAC	776	778	GAC	163;162;162	G;A;C	144;142;141	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1964	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3689	158.9	1	SNP	p	D95G	0	.	.	283	285	GAC	776	778	GAC	163;162;162	G;A;C	144;142;141	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_M_01390	mtrR.WHO_M_01390	1	1	27	906	mtrR	633	633	100.0	mtrR.l6.c4.ctg.1	1630	166.0	1	SNP	p	G45D	1	.	.	133	135	GAC	644	646	GAC	250;250;250	G;A,C,G;C	214;205,1,1;207	mtrR.WHO_M_01390:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	318	mtrR_promoter	250	250	99.6	mtrR_promoter.l6.c17.ctg.1	1361	69.6	0	.	n	.	0	G15A	SNP	15	15	G	571	571	A	54	A	49	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1970	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3346	176.3	1	SNP	p	D86N	0	.	.	256	258	GAC	836	838	GAC	199;197;197	G,C;A,C;C	165,1;156,2;166	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1970	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3346	176.3	1	SNP	p	S87R	0	.	.	259	261	AGT	839	841	AGT	193;195;196	A;G;T	162;168;161	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1970	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3346	176.3	1	SNP	p	S87I	0	.	.	259	261	AGT	839	841	AGT	193;195;196	A;G;T	162;168;161	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1970	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3346	176.3	1	SNP	p	S87W	0	.	.	259	261	AGT	839	841	AGT	193;195;196	A;G;T	162;168;161	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1970	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3346	176.3	1	SNP	p	S88P	0	.	.	262	264	TCC	842	844	TCC	195;198;199	T;C;C	162;173;174	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	1746	parE	1986	1986	100.0	parE.l15.c4.ctg.1	2980	175.2	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1709	1711	GGC	241;239;237	G;G,A;C	194;190,1;194	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.47.001	penA.47.001	1	1	27	1446	penA	1746	1746	100.0	penA.l6.c17.ctg.1	2717	159.2	1	SNP	p	A311V	0	.	.	931	933	GCC	1478	1480	GCC	204;204;204	G;C;C	165;169;170	penA.47.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.47.001	penA.47.001	1	1	27	1446	penA	1746	1746	100.0	penA.l6.c17.ctg.1	2717	159.2	1	SNP	p	I312M	1	.	.	934	936	ATG	1481	1483	ATG	203;203;201	A;T;G	167;166;166	penA.47.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.47.001	penA.47.001	1	1	27	1446	penA	1746	1746	100.0	penA.l6.c17.ctg.1	2717	159.2	1	SNP	p	T316P	0	.	.	946	948	ACC	1493	1495	ACC	204;205;207	A;C;C,A	168;174;172,1	penA.47.001:1:1:T316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.47.001	penA.47.001	1	1	27	1446	penA	1746	1746	100.0	penA.l6.c17.ctg.1	2717	159.2	1	SNP	p	V316T	1	.	.	946	948	ACC	1493	1495	ACC	204;205;207	A;C;C,A	168;174;172,1	penA.47.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.47.001	penA.47.001	1	1	27	1446	penA	1746	1746	100.0	penA.l6.c17.ctg.1	2717	159.2	1	SNP	p	T483S	0	.	.	1447	1449	ACC	1994	1996	ACC	214;215;215	A;C;C,G	171;170;175,1	penA.47.001:1:1:T483S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.47.001	penA.47.001	1	1	27	1446	penA	1746	1746	100.0	penA.l6.c17.ctg.1	2717	159.2	1	SNP	p	A501V	0	.	.	1501	1503	GCG	2048	2050	GCG	218;216;220	G,A;C,G;G	176,1;165,1;172	penA.47.001:1:1:A501V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.47.001	penA.47.001	1	1	27	1446	penA	1746	1746	100.0	penA.l6.c17.ctg.1	2717	159.2	1	SNP	p	A501P	0	.	.	1501	1503	GCG	2048	2050	GCG	218;216;220	G,A;C,G;G	176,1;165,1;172	penA.47.001:1:1:A501P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.47.001	penA.47.001	1	1	27	1446	penA	1746	1746	100.0	penA.l6.c17.ctg.1	2717	159.2	1	SNP	p	G542S	0	.	.	1624	1626	GGC	2171	2173	GGC	212;212;212	G;G;C	174;176;184	penA.47.001:1:1:G542S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.47.001	penA.47.001	1	1	27	1446	penA	1746	1746	100.0	penA.l6.c17.ctg.1	2717	159.2	1	SNP	p	G545S	0	.	.	1633	1635	GGC	2180	2182	GGC	214;215;218	G;G;C,G	174;178;182,1	penA.47.001:1:1:G545S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.47.001	penA.47.001	1	1	27	1446	penA	1746	1746	100.0	penA.l6.c17.ctg.1	2717	159.2	1	SNP	p	P551S	0	.	.	1651	1653	CCG	2198	2200	CCG	217;216;215	C;C;G	176;179;183	penA.47.001:1:1:P551S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	2020	ponA	2397	2397	99.96	ponA.l6.c4.ctg.1	3566	169.4	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	984	porA	1146	1146	99.83	porA.l15.c4.ctg.1	2174	134.8	0	.	p	.	0	M83fs	FSHIFT	247	247	A	686	686	C	152	C	132	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	124	porB1a	984	295	90.64	porB1a.l6.c4.ctg.1	1512	23.7	0	.	p	.	0	H217N	NONSYN	649	651	CAT	1242	1244	AAT	21;21;21	A;A;T	14;13;14	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	124	porB1a	984	295	90.64	porB1a.l6.c4.ctg.1	1512	23.7	0	.	p	.	0	D218N	NONSYN	652	654	GAT	1245	1247	AAT	21;21;21	A;A;T	14;14;14	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	124	porB1a	984	295	90.64	porB1a.l6.c4.ctg.1	1512	23.7	0	.	p	.	0	V226A	NONSYN	676	678	GTA	1269	1271	GCA	21;21;21	G;C;A	14;14;14	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	124	porB1a	984	295	90.64	porB1a.l6.c4.ctg.1	1512	23.7	0	.	p	.	0	.	MULTIPLE	700	702	ACT	1292	1294	GTA	20;20;19	G;T;A	14;14;13	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	124	porB1a	984	295	90.64	porB1a.l6.c4.ctg.1	1512	23.7	0	.	p	.	0	S236N	NONSYN	706	708	AGC	1298	1300	AAC	19;19;19	A;A;C	14;14;14	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	124	porB1a	984	295	90.64	porB1a.l6.c4.ctg.1	1512	23.7	0	.	p	.	0	.	MULTIPLE	709	711	AAC	1302	1306	TGGCG	19;19;19;19;19	T;G;G;C;G	13;14;14;14;14	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	124	porB1a	984	295	90.64	porB1a.l6.c4.ctg.1	1512	23.7	0	.	p	.	0	D238A	NONSYN	712	714	GAT	1308	1310	GCT	19;18;18	G;C;T	14;13;14	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	124	porB1a	984	295	90.64	porB1a.l6.c4.ctg.1	1512	23.7	0	.	p	.	0	V258L	NONSYN	772	774	GTA	1368	1370	TTA	14;14;14	T;T;A	13;13;13	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	124	porB1a	984	295	90.64	porB1a.l6.c4.ctg.1	1512	23.7	0	.	p	.	0	Y273H	NONSYN	817	819	TAT	1413	1415	CAT	13;13;13	C;A;T	13;13;13	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	124	porB1a	984	295	90.64	porB1a.l6.c4.ctg.1	1512	23.7	0	.	p	.	0	D274S	NONSYN	820	822	GAT	1416	1418	AGT	13;13;13	A;G;T	13;13;13	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	124	porB1a	984	295	90.64	porB1a.l6.c4.ctg.1	1512	23.7	0	.	p	.	0	N277Y	NONSYN	829	831	AAC	1425	1427	TAC	13;13;13	T;A;C	13;13;13	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	1084	porB1b	1035	1035	98.09	porB1b.l6.c4.ctg.1	1900	167.3	0	.	p	.	0	H39L	NONSYN	115	117	CAT	731	733	CTT	211;210;210	C,A;T;T	186,1;183;186	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	1084	porB1b	1035	1035	98.09	porB1b.l6.c4.ctg.1	1900	167.3	0	.	p	.	0	G46D	NONSYN	136	138	GGC	752	754	GAC	206;205;205	G;A;C	178;178;178	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	1084	porB1b	1035	1035	98.09	porB1b.l6.c4.ctg.1	1900	167.3	0	.	p	.	0	E48K	NONSYN	142	144	GAA	758	760	AAA	205;206;206	A;A;A	183;183;179	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	1084	porB1b	1035	1035	98.09	porB1b.l6.c4.ctg.1	1900	167.3	0	.	p	.	0	R143G	NONSYN	427	429	AGA	1043	1045	GGA	205;209;208	G,A;G;A,C	175,1;175;178,1	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	1084	porB1b	1035	1035	98.09	porB1b.l6.c4.ctg.1	1900	167.3	0	.	p	.	0	S175T	NONSYN	523	525	TCA	1139	1141	ACA	228;228;229	A;C;A	198;200;196	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	1084	porB1b	1035	1035	98.09	porB1b.l6.c4.ctg.1	1900	167.3	0	.	p	.	0	Y211fs	FSHIFT	631	631	T	1247	1247	T	240	T	211	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	1084	porB1b	1035	1035	98.09	porB1b.l6.c4.ctg.1	1900	167.3	1	SNP	p	G120K	0	.	.	358	360	GGT	974	976	GGT	206;205;205	G;G;T,G	173;167;172,1	porB1b.WHO_U_02278c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	1084	porB1b	1035	1035	98.09	porB1b.l6.c4.ctg.1	1900	167.3	1	SNP	p	A121D	0	.	.	361	363	GCC	977	979	GCC	205;206;205	G,T;C,A;C	168,1;168,1;166	porB1b.WHO_U_02278c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	1084	porB1b	1035	1035	98.09	porB1b.l6.c4.ctg.1	1900	167.3	1	SNP	p	A121N	0	.	.	361	363	GCC	977	979	GCC	205;206;205	G,T;C,A;C	168,1;168,1;166	porB1b.WHO_U_02278c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	3690	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	5210	212.2	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2151	2153	AAT	209;210;210	A,C;A;T	179,1;180;178	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	596	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1505	118.9	1	SNP	p	V57M	1	.	.	169	171	ATG	745	747	ATG	223;223;223	A;T;G	192;198;198	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
